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Introduction	
	
There	is	convincing	evidence	from	animal	and	human	studies	that	myocardial	fibrosis	
of	the	left	atrium	(LA)	and/or	the	left	ventricle	(LV),	is	involved	in	the	
pathophysiology	of	atrial	fibrillation	(AF).	The	the	role	of	LA	fibrosis	in	particular	is	of	
interest	as	a	possible	target	for	identification	of	patients	more	likely	to	benefit	from	
rhythm	control	strategies	including	ablation.	1-5	A	number	of	methods	of	quantifying	
such	fibrosis	are	available,	including	imaging	techniques	such	as	cardiovascular	
magnetic	resonance	imaging	(CMRI)	and	echocardiography,	and	minimally	invasive	
electrophysiological	(EP)	mapping.	The	role	of	circulating	biochemical	markers	is	also	
the	subject	of	interest	for	predicting	successful	rhythm	control,	and	numerous	
potential	biomarkers	have	been	studied,	with	mixed	results.	
	
In	the	context	of	catheter	ablation	of	AF,	the	majority	of	studies	assessing	fibrosis	
biomarkers	have	tested	peripheral	levels.	There	is	an	assumption	that	peripheral	
levels	of	biomarkers	will	match	intra-cardiac	levels.	However,	this	assumption	has	
not	been	conclusively	tested,	so	it	is	not	clear	whether	intra-cardiac	levels	are	indeed	
significantly	different	from	peripheral	levels.	It	is	difficult	to	conclude,	therefore,	that	
any	association	between	raised	fibrosis	markers	and	rhythm	outcome	is	necessarily	
due	to	cardiac	fibrosis,	as	opposed	to	systemic	pathology.	
	
This	study	was	undertaken	to	compare	peripheral	levels	of	four	biomarkers	of	
fibrosis	with	intra-cardiac	levels,	to	compare	levels	in	AF	patients	with	matched	
controls,	and	to	compare	the	levels	with	left	atrial	fibrosis,	assessed	by	EP	mapping	
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during	ablation.	The	biomarkers	chosen	were	pro-collagen	type	III	N-terminal	pro-
peptide	(PIIINP),	C-telopeptide	of	type	I	collagen	(ICTP),	fibroblast	growth	factor	23	
(FGF-23)	and	galectin	3	(gal-3).	In	order	to	assess	for	any	AF	–	specific	association	
with	these	biomarkers,	an	age-	and	comorbidity-matched	non-AF	control	group	was	
also	recruited	for	comparison.	
Methods	
Participants	
Ethical	approval	was	granted	by	the	National	Research	Ethics	Service	Committee	–	
Leeds	West	(ref.	13/YH/0349).	Written	informed	consent	was	obtained	from	all	
patients.	At	a	single	institution,	between	September	2014	and	August	2015,	all	
consecutive	patients	(n=98)	undergoing	first-time	left	atrial	ablation	for	paroxysmal,	
persistent,	or	long-standing-persistent	AF	were	screened.	Patients	with	systemic	
inflammatory	disease,	recent	or	active	malignancy,	severe	kidney	disease	(eGFR	<	30	
ml/min/1.73m2)	or	collagen	disease	were	excluded,	resulting	in	95	participants.	Two	
participants	subsequently	decided	against	ablation	and	withdrew	themselves	from	
the	study,	resulting	in	a	final	total	of	93	participants	in	the	AF	ablation	group.	
Recruitment	of	controls	followed	recruitment	of	AF	patients.	Patients	attending	
cardiology	clinics	for	non	–	AF	related	conditions	were	screened	and	selected	to	
create	a	control	group	with	matched	overall	population	values	for	age,	gender,	left	
ventricular	ejection	fraction	and	comorbidities.	Patients	were	excluded	from	the	
control	group	if	they	had	any	previously	documented	AF	or	other	sustained	
arrhythmia	of	any	cause,	undiagnosed	palpitations,	or	no	documentation	of	sinus	
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rhythm.	Other	control	group	exclusion	criteria	were	the	same	as	for	the	AF	group.	
	
Echocardiography	
All	participants	underwent	trans-thoracic	echocardiography	prior	to	ablation	by	a	
single	operator	with	over	5	years’	experience.	Images	were	obtained	according	to	
British	Society	of	Echocardiography	standard	guidance.	Atrial	and	ventricular	volume	
measurements	were	obtained	by	Simpson’s	biplane	method	from	apical	4-chamber	
and	2-chamber	views.	Antero-posterior	left	atrial	diameter	was	measured	in	the	2D	
parasternal	long-axis	view.	All	atrial	measurements	were	taken	at	the	end	of	
ventricular	systole.	
Serum	analysis	
Apart	from	blood	sample	collection,	ablation	procedures	were	carried	out	according	
to	standard	techniques.	Whole	blood	was	obtained	from	four	sites	per	patient	
during	the	ablation	procedure,	but	before	any	tissue	ablation	occurred.	Femoral	vein	
blood	was	aspirated	via	the	femoral	vein	sheath.	Intra-cardiac	blood	was	aspirated	
via	a	long	sheath	placed	in	the	right	atrium,	coronary	sinus	and,	after	trans-septal	
puncture,	the	left	atrium.	The	first	10ml	of	aspirate	from	the	sheath	or	catheter	was	
discarded	to	ensure	samples	were	not	contaminated	with	saline	previously	used	as	a	
flush.	Blood	was	transferred	to	sterile,	non-pyrogenic	serum	separator	tubes	and	
allowed	to	clot	for	between	30	and	60	minutes.	Tubes	were	then	immediately	
centrifuged	for	15	minutes	at	rcf	x	1600g.	Aliquots	of	the	separated	serum	were	then	
transferred	to	sterile,	non-pyrogenic	Eppendorf	tubes	and	stored	at	-70oC	until	
analysis.	Samples	were	then	thawed	prior	to	analysis,	so	underwent	only	one	freeze-
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thaw	cycle.	Blood	samples	from	control	patients	were	obtained	from	a	peripheral	
vein	using	standard	venepuncture	equipment.	
	
ELISA	
Target	biomarkers	were	analysed	using	commercially	available	enzyme-linked	
immunosorbent	assay	(ELISA)	kits.	PIIINP,	FGF-23,	and	gal-3	were	analysed	using	kits	
produced	by	Elabscience	(Beijing,	China).	ICTP	was	analysed	using	kits	produced	by	
Cusabio	Life	Science	(Wuhan,	China).	Kits	were	processed	according	to	the	
manufacturer’s	instructions.	Standards	of	known	concentration	and	serum	samples	
were	tested	in	duplicate.	Two	wells	per	plate	were	used	as	‘blanks’	to	allow	for	
background	correction.	Serum	concentrations	were	extrapolated	from	optical	
density	readings	using	a	4-parameter	logistic	curve	derived	from	the	standards.	
Inter-	and	intra-assay	coefficients	of	variation	were	<15%.		Lower	limits	of	detection	
were;	ICTP	=	25ng/ml,	gal-3	=	0.156ng/ml,	FGF-23	=	15.625pg/ml,	PIIINP	=	23.438	
pg/ml.	
Electrophysiological	mapping	
Left	atrial	bipolar	voltage	maps	were	taken	in	all	patients,	irrespective	of	rhythm,	
after	trans-septal	puncture	using	a	circular	mapping	catheter	and	either	Carto	
(Biosense	Webster)	or	NavX	Velocity	(St.	Jude	Medical)	EP	mapping	systems.	The	
minimum	mapping	time	window	for	any	electrode	position	was	2	seconds,	in	order	
to	account	for	variation	in	voltage	–	particularly	for	those	patient	in	AF	during	
mapping.	Data	from	these	systems	was	then	exported	according	to	the	
manufacturer’s	instructions	and	reformatted	to	allow	analysis	on	appropriate	
 
 
6	
AUTHOR’S ACCEPTED MANUSCRIPT 
software	according	to	previously	published	methods.6	Pulmonary	veins,	left	atrial	
appendage	and	mitral	valve	surface	were	removed	from	the	patient	specific	atrial	
anatomies	generated	during	clinical	mapping.	The	resulting	shell	was	used	to	express	
the	proportion	of	endocardial	surface	area	which	represented	fibrotic	LA	tissue	
based	on	a	voltage	value	between	0.2-0.5mV,	as	a	percentage	of	the	overall	LA	
endocardial	surface	(not	including	the	removed	structures).	Figure	1	shows	a	
representative	voltage	map.	
Statistical	analysis	
Values	are	expressed	as	either	median	(interquartile	range)	for	non-normally	
distributed	data,	or	mean	±	standard	deviation	for	normally	distributed	data.	A	p-
value	of	≤0.05	was	considered	significant.	Data	were	tested	for	normality	using	the	
Shapiro-Wilks	test,	and	non-parametric	data	underwent	logarithmic	or	square-root	
transformation	if	possible.	For	non-parametric	data,	comparison	was	made	using	
Mann-Whitney	test	for	independent	samples,	Wilcoxon’s	signed	rank	test	for	2	
paired	samples,	or	Friedman’s	test	for	3	or	more	paired	samples.	Where	Friedman’s	
test	was	significant,	post-hoc	Wilcoxon	tests	were	carried	out	between	the	groups,	
with	Bonferroni	significance	correction.	Correlations	were	examined	using	
Spearman’s	coefficient.	For	assessment	of	associations	between	baseline	
characteristics	and	biomarker	levels,	univariate	linear	regression	analysis	was	
performed,	with	mean	biomarker	levels	across	the	sample	sites	for	each	participant	
as	the	dependent	variable.	Variables	which	were	associated	with	a	significance	level	
of	p=0.100	or	less	were	then	included	in	multivariate	linear	regression	where	the	
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variable	data	was	appropriate	for	such	analysis.	Analysis	was	carried	out	using	SPSS	
version	22	and	Minitab	version	17.	
Results	
Baseline	characteristics	and	comparison	with	controls	
Table	1	shows	the	baseline	characteristics	and	comorbidities	present	within	the	
study	population,	and	comparison	between	characteristics	of	AF	and	control	groups.	
There	was	no	significant	difference	between	the	groups	in	age,	gender,	LV	ejection	
fraction,	or	comorbidity.	LA	volume	(but	not	diameter)	was	significantly	higher	in	the	
AF	group	(p=0.007).	There	was	no	significant	difference	between	levels	of	PIIINP,	
FGF-23	or	gal-3	between	the	groups,	however	there	was	a	significantly	higher	level	
of	ICTP	in	the	AF	group	(p=0.007).	
	
Table	2	shows	regression	analysis	of	relationships	between	left	atrial	biomarker	
values	and	baseline	characteristics	within	the	AF	ablation	group.		
After	multivariate	analysis,	significant	associations	were	found	between	body-mass	
index	(BMI)	and	gal-3	(p<0.001),	female	gender	and	gal-3	(p<0.001),	LV	ejection	
fraction	and	ICTP	(p=0.005),	cerebrovascular	disease	and	PIIINP	(p<0.001),	and	time	
since	AF	diagnosis	and	PIIINP	(p=0.003).	Note	that	for	LA	voltage	analysis,	values	are	
shown	separately	for	patients	in	sinus	rhythm	and	in	AF	during	EP	mapping.	There	
were	no	associations	between	biomarker	levels	and	LA	voltage-defined	fibrosis.	
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Comparison	between	blood	sample	sites	
Figure	2	illustrates	the	distributions	of	individual	biomarker	values	at	each	site.	No	
significant	difference	was	found	between	any	of	the	sites	for	FGF-23	or	PIIINP.	Gal-3	
levels	were	not	available	for	RA	and	CS	sites,	but	femoral	levels	were	significantly	
higher	than	left	atrial	levels	(p=0.001).	Femoral	ICTP	was	higher	than	LA	and	RA	
(p<0.001	for	both),	and	CS	ICTP	was	higher	than	LA	(p=0.003)	and	RA	(p<0.001).	
There	was	no	significant	difference	between	the	atria,	or	between	femoral	and	CS	
levels.	
	
Discussion	
In	this	study,	our	principal	findings	were	that	ICTP	is	higher	in	AF	patients	than	in	
matched	controls,	that	none	of	the	studied	biomarkers	were	associated	with	LA	
fibrosis	assessed	by	voltage	mapping,	and	for	gal-3	and	ICTP,	intra-cardiac	sampling	
may	be	necessary	to	assess	their	association	with	intra-cardiac	processes.		However,	
intra-cardiac	sampling	of	FGF-23	or	PIIINP	gives	no	further	information	over	
peripheral	sampling.		
	
Atrial	cardiomyopathy	has	recently	been	described	expertly	by	Goette	et	al.	in	their	
exhaustive	consensus	statement.7	Cardiac	fibrosis	is	a	hallmark	of	atrial	
cardiomyopathy	and	is	characterised	by	an	increase	in	the	turnover	of	extra-cellular	
matrix.	This	matrix	is	principally	comprised	of	type	I	and	type	III	collagen,	so	PIIINP	
and	ICTP	are	measurable	products	of	this	turnover.	Both	of	these	biomarkers	have	
shown	promise	in	the	prediction	of	rhythm	control	success.8,	9	Gal-3	has	been	shown	
to	have	direct	and	indirect	effect	on	cardiac	fibrosis	and	has	been	studied	extensively	
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in	the	context	of	heart	failure,	in	which	it	was	found	to	be	a	relatively	sensitive	and	
specific	marker	of	ventricular	dysfunction,	as	well	as	mortality.10-12		
	
FGF-23,	principally	studied	in	the	context	of	its	action	on	phosphate	homeostasis	in	
kidney	disease	and	heart	failure,	has	been	associated	with	AF,	increased	LV	mass,	
and	cardiovascular	death.	13-15	Results	of	studies	assessing	its	association	with	
incident	AF	are	mixed.	16,	17	It	has	been	shown	to	be	required	for	cardiomyocyte	
proliferation	and	differentiation	in	early	embryonic	stages	and	this	may	be	of	
interest	in	AF,	as	human	cardiomyocytes	in	vitro	have	been	shown	to	de-
differentiate	to	a	more	primitive	cell	phenotype	in	cardiac	fibrosis.	18	FGF-23	has	
been	associated	with	increased	atrial	wall	tension	as	manifest	by	raised	NT-ProBNP	
levels,	and	it	is	unclear	as	to	whether	it	has	a	direct	effect	on	the	atrial	wall,	or	
increases	LA	pressure	by	its	effect	on	LV	hypertrophy	and	fibrosis.		
	
Participants	and	generalizability	
As	far	as	we	are	aware,	this	is	the	largest	study	that	assesses	the	relationship	
between	peripheral	and	intra-cardiac	biochemical	markers	of	fibrosis	in	an	AF	
ablation	population.	The	study	population	is	representative	of	patients	undergoing	
ablation	for	AF;	despite	screening	of	all	98	consecutive	patients	listed	for	AF	ablation	
in	a	12	month	period,	only	3	patients	were	excluded,	and	2	withdrew.	The	results	are	
therefore	generalizable	to	the	wider	population	of	AF	ablation	patients.		
	
Amongst	the	AF	patient	population	as	a	whole,	such	patients	represent	a	younger,	
healthier	group	with	fewer	comorbidities,	with	males	being	over-represented.	As	
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such,	the	results	may	not	be	as	generalizable	to	AF	patient	groups	beyond	those	
suitable	for	ablation.		As	expected,	rates	of	comorbidity	(e.g.	cerebrovascular	disease	
and	renal	impairment)	were	low	in	this	population,	so	conclusions	drawn	about	
associations	between	the	biomarkers	and	comorbidities	should	be	drawn	with	
caution.	
It	should	also	be	noted	that	there	is	a	large	element	of	scatter	amongst	the	
biomarker	readings	as	can	be	seen	in	figure	2	and	the	inter-quartile	ranges	of	the	
biomakers.	Despite	this,	however,	statistically	significant	differences	between	the	
biomarker	distributions	could	still	be	determined.	
	
Relationship	between	intra-cardiac	and	femoral	levels	
Peripheral	sampling	of	all	four	of	these	biomarkers	proportionally	represents	their	
intra-cardiac	levels.	In	the	case	of	PIIINP	and	FGF-23,	the	lack	of	difference	between	
peripheral	and	intra-cardiac	levels	suggests	that	these	biomarkers	may	reflect	
systemic	fibrosis	(or	other	non-fibrotic	processes	in	which	they	are	involved).	In	the	
case	of	ICTP	and	gal-3,	levels	are	higher	peripherally.	Therefore,	it	cannot	be	
concluded	that	the	heart	is	the	main	source	of	these	substances	in	the	bloodstream.	
Systemic	rather	than	cardiac	pathology	may,	therefore,	be	the	principal	driver	
behind	any	association	between	these	biomarkers	and	successful	treatment	of	AF.	
Such	findings	are	in	agreement	with	the	study	by	Okumura	et	al.,	which	showed	no	
difference	between	intra-cardiac	and	femoral	levels	of	their	chosen	inflammation	
and	extra-cellular	matrix	turnover	markers	(which	included	ICTP)	in	25	ablation	
patients.	8	
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Intra-cardiac	differences	
PIIINP	and	FGF-23	were	not	significantly	different	between	intra-cardiac	sites.	
Therefore,	any	fibrosis	present	within	the	myocardium	does	not	appear	to	
contribute	to	a	detectable	increase	of	these	compounds	in	the	blood.	However,	ICTP	
was	higher	in	the	CS	than	either	the	LA	or	the	RA.	This	suggests	that	ICTP	enters	the	
bloodstream	from	the	myocardium	at	detectable	levels,	although,	as	discussed,	this	
is	masked	in	peripheral	blood.	This	finding	does	not	distinguish	between	ICTP	arising	
from	the	ventricle	or	the	atrium.	
	
Relationship	with	baseline	characteristics	
In	this	study	we	found	no	evidence	to	support	a	relationship	between	the	
biomarkers	and	simple	baseline	echocardiographic	markers	of	left	atrial	remodelling.	
Neither	was	there	any	relationship	with	AF	classification,	(paroxysmal	vs.	non-
paroxysmal	patients),	however	PIIINP	was	associated	with	duration	of	AF,	measured	
by	time	since	reported	clinical	diagnosis.	PIIINP	has	been	shown	to	have	a	complex	
relationship	with	AF	incidence,	with	mixed	results	regarding	its	association	with	AF	
duration.19	More	work	is	required	to	understand	the	role	PIIINP	may	play	in	relation	
to	the	temporal	progression	of	the	disease.	The	BMI	and	gender	associations	which	
we	encountered	with	gal-3	have	been	previously	described	in	other	patient	groups.	
20,	21	A	relationship	between	ICTP	and	ventricular	function	has	also	been	described,	
to	a	much	lesser	extent.	This	study	was	not	designed	to	examine	such	an	association,	
and	as	only	5	patients	had	a	reduced	LVEF,	further	studies	are	required.	Similarly,	
although	an	association	between	PIIINP	and	cerebrovascular	disease	was	found	in	
 
 
12	
AUTHOR’S ACCEPTED MANUSCRIPT 
this	study,	this	was	based	on	only	5	patients	and	should	be	interpreted	with	
appropriate	caution.	
	
Relationship	with	LA	voltage	data	
The	presence	of	low	voltage	areas	within	the	LA	has	been	shown	to	be	an	
independent	predictor	of	AF	recurrence	after	ablation,	and	there	is	evidence	that	
these	areas	of	low	voltage	are	associated	with	fibrosis	identified	with	MRI.	22,	23	
Voltage	criteria	for	identifying	such	areas	are	not	universally	established,	however	
studies	have	addressed	the	issue.	22,	24	The	definition	of	‘low	voltage’	in	this	study	
(0.2-0.5mV)	is	drawn	from	these	studies.	The	lower	value	chosen	was	0.2mV	rather	
than	0mV	to	reduce	artefact	caused	by	poor	contact	between	the	mapping	catheter	
and	the	endocardium.	Assuming	that	this	method	is	a	consistent	index	of	LA	fibrosis,	
the	results	suggest	that	levels	of	these	four	biomarkers	are	not	reflective	of	atrial	
fibrosis.	For	the	biomarkers	where	there	is	some	prior	evidence	of	predictive	value	
of	arrhythmia	recurrence	(PIIINP,	ICTP	and	gal-3),	this	may	reflect	their	involvement	
in	fibrosis	elsewhere	in	the	heart	(e.g.	the	LV),	or	elsewhere	in	the	body.	
	
Implications	
PIIINP	and	gal-3	levels	have	been	associated	with	incidence	of	AF,	but	their	use	in	the	
prediction	of	catheter	ablation	success	has	yielded	mixed	results.12,	25,	26	This	study	
may	help	to	explain	why	this	is	the	case,	as	it	suggests	that	systemic	(or	at	least	non-
atrial)	factors	may	have	the	prominent	role	in	their	presence	in	the	circulation,	as	
evidenced	by	the	lack	of	difference	in	matched	controls.	If	cardiac	fibrosis	is	the	
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critical	component	determining	success	in	AF	ablation,	then	such	markers	may	have	
limited	use	in	this	role.		
	
No	studies	have	addressed	the	clinical	utility	of	FGF-23	in	predicting	the	success	of	
AF	ablation,	and	the	findings	presented	here	suggest	such	utility	may	be	limited.	On	
the	other	hand,	ICTP	does	appear	to	be	involved	in	local	cardiac	fibrosis	and	this	may	
help	to	explain	why	it	has	shown	more	promise.	In	this	study,	however,	we	have	
shown	that	ICTP	does	not	appear	to	be	significantly	associated	with	LA	fibrosis.	
Therefore,	it	is	potentially	fibrosis	elsewhere	within	the	heart,	most	likely	the	LV,	
which	the	increased	CS	ICTP	levels	reflect.	
Conclusion	
ICTP	levels	are	associated	with	the	presence	of	AF	in	comparison	with	non-AF	
controls.	PIIINP	levels	are	associated	with	AF	duration.	None	of	ICTP,	PIIINP,	gal-3	or	
FGF-23	appear	to	reflect	atrial	fibrosis	when	assessed	by	voltage	mapping	criteria.	
Intra-cardiac	sampling	of	FGF-23	or	PIIINP	gives	no	further	information	over	
peripheral	sampling.	For	gal-3	and	ICTP,	intra-cardiac	sampling	may	be	necessary	to	
assess	their	association	with	intra-cardiac	processes.	
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Figure	1.	Representative	left	atrial	voltage	map.	Areas	in	red	represent	voltage	of	0.2-
0.5mV.	Pulmonary	veins	and	left	atrial	appendage	were	removed	prior	to	analysis.	
	
Figure	2.	Individual	value	plots	of	biomarker	levels	at	each	sample	site,	with	median	values.	Arrows	
on	ICTP	plot	represent	results	of	post-hoc	testing	of	between-group	differences.	
